Skip to main content
Equibles
DERM logo

DERM · Journey Medical Corp · Metrics

Track DERM — free

Use DERM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DERM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.69 +0.08 (+1.21%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, as a result of recurring and historical losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.”
View the 10-Q filed Aug 12, 2026
Market Cap
$188.54M
Shares
28.22M
Volume · Oct 5 88.75K Avg daily vol (3M) 184.12K

DERM metrics

66 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.61
Market cap
$188.54M

Price action

20 metrics
Price change (1W)
+7.7%
Price change (30D)
-15.9%
Price change (3M)
-6.8%
Price change (6M)
+33.5%
Price change (YTD)
-14.3%
Price change (1Y)
-9.5%
Trailing year
Price change (5Y)
—
52-week high
$9.26
52-week low
$4.39
Change from 52-week high
-28.6%
Change from 52-week low
+50.6%
Annualized volatility
65.1%
Annualized volatility (3M)
54.9%
Beta
1.7
RSI (14D)
43.7
Price vs SMA 50
-4.8%
Price vs SMA 200
-3.7%
Avg volume (3M)
184,123
Relative volume
0.7
Average dollar volume
$1.26M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
28.22M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.8×
reciprocal yield 36.2%
EV / EBITDA
—
EV / EBIT
—
P / sales
2.8×
reciprocal yield 36.2%
P / book
5.9
reciprocal yield 17.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.2×
reciprocal yield 46.1%
EV / revenue historical average (5Y)
1.7×
reciprocal yield 57.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
66.2%
Operating margin
-4.4%
Trailing 12 months
Net margin
-9.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$3.01M
Net income (TTM)
−$6.10M
Trailing 12 months
Diluted EPS (TTM)
$-0.22
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$3.01

Growth

11 metrics
Revenue growth YoY
+23.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$68.18M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+18.0%
Year over year · more shares
Revenue CAGR (3Y)
-5.7%
Revenue CAGR (5Y)
+6.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-19.0%
Return on assets
-6.2%
Debt / equity
0.8
Current ratio
1.6
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.4
Interest coverage
-0.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$171,000
Latest balance sheet
Cash & equivalents
$25.64M
Total assets
$98.36M
Total debt
$25.47M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.49M
Capital expenditures (TTM)
$5.00M
R&D (TTM)
$495,000
SG&A (TTM)
$42.91M
Stock compensation (TTM)
$6.05M
R&D / revenue
—
Stock compensation / revenue
8.9%

Ownership (13F)

3 metrics
13F filers
71
13F filer change QoQ
-2
Institutional ownership
37.7%

Short interest

3 metrics
Short interest
10.4%
Latest settlement · 22.5 days to cover
Days to cover
22.5d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1867066 CUSIP 48115J109 13F (30d) 3 filings 3 filers Visit website Investor relations